Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors

Thrombosis and Haemostasis

Volumn 105, Issue 6, 2011, Pages 954-961

  Lebreton, Aurélien ^a   Lapalud, Priscilla ^a   Chambost, Hervé ^b   Biron Andreani, Christine ^c   Morange, Pierre Emmanuel ^b   Combescure, Christophe ^d   Marques Verdier, Alain ^e   Berger, Claire ^f   Schved, Jean François ^c   Granier, Claude ^a   Lavigne Lissalde, Géraldine ^a,c  

^a UMR 3145 SysDiag CNRS/Bio Rad   (France)

^b TIMONE HOSPITAL   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Epitope mapping; Factor VIII; Haemophilia A; Non neutralising antibodies; x MAP technology

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CHILD; CHROMOSOME INVERSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ANTIGENICITY; EPITOPE MAPPING; GENE MUTATION; HEMOPHILIA A; HUMAN; IMMUNOREACTIVITY; INTRON; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTIBODIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; EPITOPE MAPPING; EPITOPES; FACTOR VIII; FEMALE; FRANCE; HEMOPHILIA A; HUMANS; IMMUNODOMINANT EPITOPES; INFANT; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 79958103897     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-10-0668     Document Type: Article

References (41)

1. Hoyer LW. Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Hum Pathol 1987; 18: 153-161.
2. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-174.
3. Lollar P, Parker CG. Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 1989; 28: 666-674.
4. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312: 337-342.
5. Toole JJ, Pittman DD, Orr EC, et al. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-5942.
6. Lavigne-Lissalde G, Schved JF, Granier C, et al. Anti-factor VIII antibodies: a 2005 update. Thromb Haemost 2005; 94: 760-769.
7. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999; 5: 1044-1047.
8. Kazatchkine MD, Sultan Y, Burton-Kee EJ, et al. Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A. Clin Exp Immunol 1980; 39: 315-320.
9. Di Giambattista M, Branckaert T, Laub R. Mapping of natural anti-factor VIII antibodies in plasma pools from healthy donors: use of rationally designed synthetic peptides. Biologicals 2001; 29: 229-232.
10. Kasper CK, Pool JG. Letter: Measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh 1975; 34: 875-876.
11. Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2010; 16: 20-24.
12. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
13. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
14. Dazzi F, Tison T, Vianello F, et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996; 93: 688-693.
15. Ling M, Duncan EM, Rodgers SE, et al. Low detection rate of antibodies to nonfunctional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1: 2548-2553.
16. Vincent AM, Lillicrap D, Boulanger A, et al. Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates. Haemophilia 2009; 15: 374-376.
17. Krudysz-Amblo J, Parhami-Seren B, Butenas S, et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113: 2587-2594.
18. Lavigne-Lissalde G, Lacroix-Desmazes S, Wootla B, et al. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice. Thromb Haemost 2007; 98: 138-147.
19. Bovenschen N, Rijken DC, Havekes LM, et al. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005; 3: 1257-1265.
20. Lavigne-Lissalde G, Tarrade C, Lapalud P, et al. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 2008; 99: 1090-1096.
21. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
22. Martin PG, Sukhu K, Chambers E, et al. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999; 21: 125-128.
23. Blanco AN, Peirano AA, Grosso SH, et al. An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients. Haematologica 2000; 85: 1045-1050.
24. Sahud MA, Pratt KP, Zhukov O, et al. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 2007; 13: 317-322.
25. Vianello F, Radossi P, Tison T, et al. Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22. Br J Haematol 1997; 97: 807-809.
26. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-1505.
27. Lorenzo JI, Lopez A, Altisent C, et al. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-603.
28. van der Bom JG, Mauser-Bunschoten EP, Fischer K, et al. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-479.
29. Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
30. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-155.
31. Scandella D, Mondorf W, Klinge J. The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Haemophilia 1998; 4: 546-551.
32. Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 1993; 82: 1767-1775.
33. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-1819.
34. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-246.
35. Batlle J, Gomez E, Rendal E, et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996; 72: 321-326.
36. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-766.
37. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-8962.
38. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009; 15: 1187-1196.
39. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-1406.
40. Astermark J, Voorberg J, Lenk H, et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-572.
41. Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost 2010; 104: 931-940.